Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Soluble CD95 Ligand Role in the Pathophysiology of ANCA Associated Vasculitis

ID
Name
CHUBX 2018/22
Description
The study aims at defining the role of soluble CD95 Ligand in the physiopathology of a rare group of inflammatory diseases: ANCA associated vasculitis. Soluble CD95 Ligand might have a prognostic and diagnostic interest as well as potential for the discovery of new therapeutic strategies.
Trial arms
Trial start
2018-12-14
Estimated PCD
2024-12-01
Trial end
2024-12-01
Status
Recruiting
Treatment
blood sample
30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
Arms:
ANCA associated vasculitis
urine sample
6 ml
Arms:
ANCA associated vasculitis
Size
50
Primary endpoint
Change of quantitative levels of s-CD95-L in ANCA associated vasculitis between baseline and Month 12
At baseline (Day 0) and 12 months from baseline
Eligibility criteria
Inclusion Criteria: * Diagnosis of ANCA associated vasculitis according to the Chapel-Hill Consensus Conference - 2012 modified version * Age ≥ 18 years * being affiliated to health insurance * willing to participate and to sign informed consent. Exclusion Criteria: * Pregnant or breastfeeding women, * patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 50, 'type': 'ESTIMATED'}}
Updated at
2024-04-26

1 organization

2 products

1 indication

Organization
University Hospital Bordeaux
Product
Blood sample
Indication
ANCA-Associated Vasculitis
Product
Urine Sample